Clinical trial data can be remarkably (and unnecessarily) difficult to read. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it.
STAT national biotech columnist Adam Feuerstein and STAT senior science writer Sharon Begley shared tips of the trade in this subscriber-only webinar. They offered their recommendations on what to look for — and what not to fall for — when trying to make sense of clinical trial data.